Vima banks $100m in Series A to progress Parkinson’s drug
Massachusetts-based biotech Vima Therapeutics has extended its Series A financing by $40m to advance its investigational Parkinson’s and dystonia pill,…
12 Mar 2026
Eli Lilly finds impurity in compounded tirzepatide
Eli Lilly has warned of high levels of an impurity in certain compounded versions of its blockbuster glucagon-like peptide-1 receptor agonist (GLP-1RA) tirzepatide. Lilly issued the public warning after conducting…
12 Mar 2026
Bavarian Nordic and SII sign agreement for chikungunya vaccine production
Bavarian Nordic has signed a manufacturing agreement with Serum Institute of India (SII), expanding its strategic partnership through a contract for its chikungunya vaccine (CHIKV VLP). The contract covers a…
12 Mar 2026
Curatis and Neupharma sign development agreement for corticorelin in Japan
Switzerland-based Curatis has signed an exclusive licensing and development agreement with Neupharma for corticorelin (C-PTBE-01) to treat peritumoral brain oedema in Japan. Neupharma will gain exclusive rights for the development…
11 Mar 2026
FDA issues warning to Novo Nordisk on unreported semaglutide safety events
Novo Nordisk has received a warning letter from the US Food and Drug Administration (FDA) related to the company’s failure to investigate and flag treatment-emergent adverse events (AEs) associated with…
11 Mar 2026
Eli Lilly to invest $3bn in China in anticipation of orforglipron approval
Eli Lilly is continuing its global investment drive to ensure it can meet future demand for its highly anticipated oral weight loss drug orforglipron, outlaying $3bn to expand its supply…
11 Mar 2026
BioNTech co-founders step down to launch new mRNA venture
The co-founders of BioNTech will leave the company to launch a new mRNA-focused entity, amid mounting losses for the vaccine specialist. Uğur Şahin and Özlem Türeci established BioNTech in 2008…